Ethosuximide in the treatment of absence (peptit mal) seizures. - Wikidata - awgldk - TriplyDB

Ethosuximide in the treatment of absence (peptit mal) seizures.

Ethosuximide in the treatment of absence (peptit mal) seizures.

http://www.wikidata.org/entity/Q45215486

about

Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons The cognitive impact of antiepileptic drugs.Ethosuximide Induces Hippocampal Neurogenesis and Reverses Cognitive Deficits in an Amyloid-β Toxin-induced Alzheimer Rat Model via the Phosphatidylinositol 3-Kinase (PI3K)/Akt/Wnt/β-Catenin Pathway Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs.Ethosuximide: from bench to bedside.Neuropsychological deficits in childhood epilepsy syndromes.The epileptic hypothesis: developmentally related arguments based on animal models.Developmental neuropsychiatry.Cognitive function of idiopathic childhood epilepsy.Current and emerging treatments for absence seizures in young patients Teratogenicity of anticonvulsant drugs. II: A prospective study.Syndromes of epilepsy in childhood and adolescence.Use of antiepileptic drugs in the presence of liver and kidney diseases: a review.Rational usage of therapeutic drug monitoring in antiepileptic treatment.Testing antiepileptic drugs in children.Antiepileptic drug development: I. History and a program for progress.Computer model of ethosuximide's effect on a thalamic neuron.Actions of U-92032, a T-type Ca2+ channel antagonist, support a functional linkage between I(T) and slow intrathalamic rhythms.Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: GABA current blockade.Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study.Effects of antiepileptic drugs and seizure type on operant responding in mentally retarded persons.

P2860

Q24673531-19B5A3F2-E779-450A-A6B6-A90080C27F91 Q28342691-8B436A67-1503-4596-99F2-6E6D1B35D272 Q35588407-13125256-F1BA-42E4-BF5A-69FA8752110E Q36301359-13496A37-0416-4F4A-8736-B2510AB2A9E0 Q36319435-C0E1A974-B32D-4F1E-8F94-98F0453574D5 Q36879564-45A6F6B2-F329-47E2-B2C0-E6AEFE3B934E Q36982516-293ABE16-9F36-46A9-BF5D-2D99CD59924C Q37328931-FD38DB27-2D9D-4E77-AF63-6745B0D64623 Q37727035-3A2BBBB8-B9A2-4E1E-9D79-2C90BA210A04 Q38016420-1EB67635-9194-4627-A2B3-E6194A24FEAC Q38124030-718460D8-89E8-4DE4-AB92-67C552A342A5 Q39346774-0D626FDB-11C6-4BB0-8D6C-A8868156E674 Q39552255-C9998824-4EBC-4E2B-B1A2-4EED5708496A Q40266496-41A169EF-C5EA-41E4-8BDC-15001E850EE4 Q40285712-150800B0-E42D-40E2-9810-C7C1B4905485 Q40570299-C292558D-2232-4F0B-B25F-09F4A44C5EB8 Q40943516-0C3673A2-3D3A-4920-84F7-2B39113D9EF0 Q41109361-CD03F5DD-F31B-4ECD-8E09-B2B63ACE502C Q42435541-CECFCEA9-3E59-483E-A378-3252F452C859 Q42563409-C0872883-6CCA-4664-81FA-D4AA53ABACDF Q45030236-E60EE2A6-16FC-428D-A1F6-53F5E2B40528 Q49075329-28D64926-65D2-406F-80D4-CB5438DDB2F3

P2860

Ethosuximide in the treatment of absence (peptit mal) seizures.

http://www.wikidata.org/entity/Q45215486

description

1975 nî lūn-bûn

@nan

1975年の論文

@ja

1975年学术文章

@wuu

1975年学术文章

@zh

1975年学术文章

@zh-cn

1975年学术文章

@zh-hans

1975年学术文章

@zh-my

1975年学术文章

@zh-sg

1975年學術文章

@yue

1975年學術文章

@zh-hant

name

Ethosuximide in the treatment of absence (peptit mal) seizures.

@en

Ethosuximide in the treatment of absence

@nl

type

label

Ethosuximide in the treatment of absence (peptit mal) seizures.

@en

Ethosuximide in the treatment of absence

@nl

prefLabel

Ethosuximide in the treatment of absence (peptit mal) seizures.

@en

Ethosuximide in the treatment of absence

@nl

P1433

Q45215486-178A5902-96E7-4316-B796-10C015662619

P1476

Q45215486-FE0FA137-6C09-4C60-8F80-29D036BA0426

P2093

Q45215486-26A6AA1A-B489-43E3-9567-4616D6196047

Q45215486-3CF402AE-FE6D-46E5-8137-50596C45565F

Q45215486-4DE130FF-2B8A-42BF-BD23-4AEF25B350B1

Q45215486-9A448875-BFCD-4C0B-BC46-574D550AAA74

Q45215486-CD5078DF-770D-4717-9C25-1E99E4B45975

Q45215486-DD21D272-6D6F-4BD9-892E-7975A1281814

Q45215486-DF807EEB-A336-4D1A-9891-D8DFF46FA747

Q45215486-FBFE78C3-9B73-4164-9ADE-39BCCA8BA8A8

P304

Q45215486-067E3E52-A5B2-43DC-BE8D-22587EE824F5

P31

Q45215486-A7B73525-A9B7-49E9-A6EF-BC2FE31B088A

P356

Q45215486-1A68CB30-3E57-45E0-99E6-40BF7144AF10

P407

Q45215486-D2F2FB89-DEFD-4355-A9AE-5F6A679FA572

P433

Q45215486-DE5E4349-C2F2-43D0-8F6C-97C0E0E14856

P478

Q45215486-1EC4214A-9876-4CD9-8318-7AD045385017

P577

Q45215486-BCD8A65D-11F3-4262-9CD4-0A30EA2933B9

P698

Q45215486-116EE9FF-C2CB-4762-A6BA-6CDD38F97BA4

P356

P1433

P1476

Ethosuximide in the treatment of absence (peptit mal) seizures.

@en

P2093

Browne TR

http://www.w3.org/2001/XMLSchema#string

Dreifuss FE

http://www.w3.org/2001/XMLSchema#string

Dyken PR

http://www.w3.org/2001/XMLSchema#string

Goode DJ

http://www.w3.org/2001/XMLSchema#string

Penry JK

http://www.w3.org/2001/XMLSchema#string

Porter RJ

http://www.w3.org/2001/XMLSchema#string

White BG

http://www.w3.org/2001/XMLSchema#string

White PT

http://www.w3.org/2001/XMLSchema#string

P304

515-524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.25.6.515

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

1975-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

805382

http://www.w3.org/2001/XMLSchema#string